Enhanced Implantable Biotherapeutic Agent Delivery System

Publication ID: 24-11857672_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Implantable Biotherapeutic Agent Delivery System,” Published Technical Disclosure No. 24-11857672_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857672_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,672.

Summary of the Inventive Concept

An advanced nanoporous canister with a bicontinuous morphology for delivering biotherapeutic agents, enhancing cell survival and promoting tissue repair in mammalian hosts.

Background and Problem Solved

The original implantable cellular and biotherapeutic agent delivery canister patent had limitations in terms of cell survival, surface area exposure, and biocompatibility. The new inventive concept addresses these limitations by introducing a bicontinuous morphology, surface treatment patterns, and coatings to improve the device's performance and safety.

Detailed Description of the Inventive Concept

The enhanced system consists of a nanoporous canister with a bicontinuous morphology, designed to wholly isolate a therapeutically active agent and/or cells therein. The canister features a rigid, nanoporous structure with two nanoscale through-porous regions, allowing for diffusion of therapeutic metabolites and nutrients/waste products. A surface treatment pattern increases the surface area of exposure, while a coating reduces inflammation and promotes tissue integration. The system can be monitored using a sensor to detect changes in therapeutic metabolite concentrations.

Novelty and Inventive Step

The new claims introduce the bicontinuous morphology, surface treatment patterns, and coatings, which are not present in the original patent. These innovations provide a significant improvement in cell survival, biocompatibility, and overall device performance.

Alternative Embodiments and Variations

Alternative embodiments could include modifying the nanoporous structure's geometry, using different materials for the coating, or integrating additional sensors for real-time monitoring. Variations could also involve adapting the device for different therapeutic applications or target tissues.

Potential Commercial Applications and Market

The enhanced implantable biotherapeutic agent delivery system has significant commercial potential in the fields of regenerative medicine, tissue engineering, and biomedical devices. Target industries include pharmaceutical companies, medical device manufacturers, and research institutions focused on developing novel therapies for various diseases and conditions.

CPC Classifications

SectionClassGroup
A A61 A61K9/0024
A A61 A61F2/022
A A61 A61K31/337
A A61 A61K31/397
A A61 A61K31/436
A A61 A61K31/65
A A61 A61K31/7036
A A61 A61K35/28
A A61 A61K38/14
A A61 A61K38/1866
A A61 A61K38/22
A A61 A61K39/395
A A61 A61K47/02
A A61 A61M39/0247
A A61 A61M2039/027
A A61 A61M2039/0261
A A61 A61M2039/0276
A A61 A61M2205/04

Original Patent Information

Patent NumberUS 11,857,672
TitleImplantable cellular and biotherapeutic agent delivery canister
Assignee(s)NanoVault Medical LLC